- Home
- PLX
as 11-21-2024 4:00pm EST
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
| Founded: | 1993 | Country: | Israel |
| Employees: | N/A | City: | HACKENSACK |
| Market Cap: | 79.4M | IPO Year: | 1998 |
| Target Price: | N/A | AVG Volume (30 days): | 439.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.82 - $1.90 | Next Earning Date: | 11-14-2024 |
| Revenue: | $45,667,000 | Revenue Growth: | -28.22% |
| Revenue Growth (this year): | -17.21% | Revenue Growth (next year): | 88.94% |
Latest Protalix BioTherapeutics Inc. (DE) News
PLX Breaking Stock News: Dive into PLX Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
6 days ago
PLX: Self-Sustaining Rise to Lead in Renal Rare Disease
GuruFocus.com
7 days ago
Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...
Associated Press Finance
7 days ago
Protalix: Q3 Earnings Snapshot
PR Newswire
7 days ago
Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results
PR Newswire
14 days ago
Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024
Simply Wall St.
21 days ago
Accolade And 2 Other Penny Stocks To Watch On US Exchanges
PR Newswire
a month ago
Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024
Zacks Small Cap Research
a month ago
OTC Markets Hosts Virtual Investor Presentation with Dror Bashan, President & CEO of Protalix Biotherapeutics, and John Vandermosten, Senior Analyst at Zacks SCR
Compare PLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLX Protalix BioTherapeutics Inc. (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.